Financing channel feed – Endpoints News

Financing channel feed

The top 100 venture players in biopharma today. Who's in? What's out?

Last year

Exclusive: Dupixent in a pill? Startup Insamo will try to turn blockbuster biologics into orals

Last year

Owkin launches new startup to ‘capture laws of biology’ with $35M seed round

Last year

Sofinnova’s Maha Katabi on recent M&A and IPO success and how deal flow has ‘never been any better’

Last year

Athos, an autoimmune and cancer biotech, is raising $35M for clinical trials

Last year

Apnimed, a late-stage sleep apnea biotech, eyes IPO in the second half

Last year

Carolyn Bertozzi and Versant's new biotech breaks cover with $94M to use protein degraders in ADCs

Last year

Freenome raises $254M for early cancer detection tests

Last year

Two SPAC’d biotechs raise additional money as Bihua Chen’s blank check closes $184M IPO

Last year

Latigo, a pain biotech years in the making, emerges with $135M on heels of Vertex PhIII success

Last year

European investor Earlybird Health closes $185M fund to back 12 to 15 companies

Last year

The Endpoints Slack interview: Zavain Dar on starting a new VC, trusting the process with the 76ers, and Apple's VR future

Last year

BioAge raises $170M as obesity spotlight shifts to oral options, muscle preservers

Last year

Seattle biotech founded by former Seagen leaders nabs $112M for three clinical-stage ADCs

Last year

Centessa 2.0 with a twist: Medicxi combines six immuno-derm startups with $100M

Last year

Preclinical biotech Metagenomi prices $94M IPO at low end of proposed range

Last year

Neurona raises $120M to take epilepsy cell therapy to late-stage development

Last year

Kyverna lands $319M IPO as autoimmune CAR-T field has its moment in the sun

Last year

Exclusive: With an eye toward expansion, an AI company that supports CDMOs completes $20M Series C raise

Last year

A new VC fund emerges with $310M to create independent, commercial biotechs

Last year

Gene editing startup Metagenomi finally sets IPO range, as preclinical biotech eyes $87M

Last year

ARCH, one of life sciences' premier investors, eyes $3B for 13th fund

Last year

Alto Neuroscience and Fractyl Health add to biotech IPO momentum in Friday doubleheader

Last year

Exclusive: Column Group raises a new $400M+ fund and R&D hub for single-asset biologics companies

Last year

First page Previous page 18 19 202122 23 24 Next page Last page